In the Election Day scramble you might have missed that Pfizer got a new drug approved for rheumatoid arthritis Pfizer expects the twiceaday pill called   will be available in pharmacies later this month The drug wont come cheap The wholesale price will run about  for a months supply the company says There are lots of other treatments for rheumatoid arthritis Theres an inexpensive generic pill called   And there are some pricier options  Remicade Enbrel and Humira to name three  that require a needle But this rheumatoid arthritis drug is the first one that works by blocking enzymes called   They play a communication role inside the body and are involved in inflammation associated with rheumatoid arthritis Pfizer says Xeljanz say zeljans costs less than the two leading brandname rheumatoid arthritis treatments But not a lot less according to data from health industry analyst   at ISI Group He figures a year of treatment with Xeljanz would run only  or so less than treatment with Enbrel or Humira Xeljanz is for patients with moderatetosevere rheumatoid arthritis who either cant tolerate or dont respond to methotrexate the Food and Drug Administration   In a presentation to investors Schoenbaum wrote that he expected doctors to use the drug cautiously and mainly in patients who had failed Enbrel and Humira The new   come with a boxed warning the most serious type of safety information required by FDA Xeljanz carries a risk of serious infections including tuberculosis and some illnesses that required hospitalization in clinical tests The drug also raises cholesterol It was also associated with an increased risk for some cancers Pfizer agreed to study those side effects in a longterm study